Atrial Fibrillation Surgery Market Snapshot
2018 - 2026
Need a report that reflects how COVID-19 has impacted this market and its growth?
The Atrial Fibrillation Surgery Market is expected to register a CAGR of nearly 12.2% during the forecast period.
The COVID-19 patients with cardiovascular disorders are at high risk and are most vulnerable to multiple organ failure including myocarditis and rhythm disturbance. The data from Wuhan, China has indicated that arrhythmia and acute cardiac injury were amongst the most prevalent heart complications in confirmed-positive cases of COVID 19. Further, the February 2020 case report in the Journal of the American Medical Association (JAMA) identified common complications, such as shock (8.7%), acute respiratory distress syndrome (19.6%), arrhythmia (16.7%), and acute cardiac injury (17.2%) among hospitalized patients. Moreover, patients who received care in the ICU were more likely to have one of these complications than non-ICU patients.
Moreover, owing to the evolving public health crisis of COVID-19, remote monitoring allows clinicians to maintain necessary patient rapport with their healthcare provider when required. Health care providers can access information remotely about a patient's health while the patient is at home, which will reduce the need for hospital visits and minimizing the risk of exposure to COVID-19. The article 'Home Monitoring of Cardiac Devices in the Era of COVID-19', published in 2020 concludes that new technologies and digital platforms to aid in remote care should be developed and further research on the role of telehealth, continuous data collecting, advanced automotive features, and remote patient monitoring is needed to guide best practices, which may fuel the growth of studied market.
The atrial fibrillation market is driven by rising prevalence of obesity and heart diseases across the globe. Additionally, heart diseases are one of the major cause of mortality across the globe and due to the changing lifestyle, the number of people suffering from heart diseases is growing rapidly.
Atrial Fibrillation (AFib) is the most prevalent chronic arrhythmia in patients above 65 years of age. As per the Centers for Disease Control and Prevention (CDC) estimates around 12.1 million people in the United States will have AFib by 2030. With the growth in the aging population, this number is expected to increase. Thus, the increasing incidences of CVD and atrial fibrillation are expected to augment the growth of the market studied and is posing a high burden on the economies of various countries due to the high cost of treatment. Hence, owing to the aforementioned factors, the market studied is expected to grow in the forecast period.
Scope of the Report
As per the scope of the report, atrial fibrillation (AF) is a common abnormal heart rhythm that occurs when electrical impulses fire off from different places in the atria in a disorganized way.
The atrial fibrillation surgery market is segmented by product (catheter ablation and surgical ablation), end-user (hospitals, ambulatory surgical centers, and others), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa and South America). The report offers the value (in USD million) for the above segments.
|Ambulatory Surgical Centers|
Key Market Trends
Ambulatory Surgical Center Segment is Expected to Witness Good Growth over the Forecast Period
The ambulatory surgical center segment is expected to witness good growth due to enhanced healthcare infrastructure, availability of skilled labor, and affordability. The rising patient pool, growing geriatric population suffering from lifestyle diseases, such as atherosclerosis and heart failure, is expected to propel the market. However, as compared to conventional surgeries, the benefits of minimally invasive surgeries will ultimately lead to segment growth. Benefits, such as reduced surgical pain, injury, hospital stay, higher accuracy, and speedy recovery time are encouraging patients to opt for minimally invasive surgeries, which is expected to boost the market growth.
In addition, owing to the increasing burden of obesity, there is an increase in the number of people suffering from atrial fibrillation. Hence, it is believed that an increased prevalence of obesity is contributing to the growth of the market.
Owing to the COVID-19 situation, it was observed that obesity had increased. According to an article published by the European Journal of Nutrition in December 2020, the rate of obesity has increased in the world. The major reason includes change in lifestyle and a decreased physical activity among people. This increase in the obesity population is expected to drive the studied market in the near future.
To understand key trends, Download Sample Report
North America is the Largest Growing Segment over the Forecast Period
The North American region is expected to dominate the atrial fibrillation market. This is majorly attributed to the rising patient pool in the region and the presence of key players. As per the statistics provided by the CDC (Centre for Disease Control and Prevention), in 2017, around 2.7 to 6.1 million people in the United States had AFib and with the rising geriatric population, it is expected that the demand of the studied market will grow in the future. As per American Heart Association (2018), high blood pressure is one of the leading causes of atrial fibrillation that accounts for approximately 14% to 22% of all AFib cases in the United States.
With the presence of key players in the country, technological advancements, and availability of favorable insurance policies are augmenting the growth of the market studied in the United States. For instance, in July 2020, Boston Scientific Corporation announced that it has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device, which is indicated to reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) who requires alternative to oral anticoagulation therapy.
To understand geography trends, Download Sample Report
The market for atrial fibrillation consists of local as well as global companies, which are focusing on the development of new product launches and also witnessing penetration of new entrants in the market. In May 2020, CardioFocus, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the next-generation HeartLight X3 Endoscopic Ablation System for the treatment of drug-refractory recurrent symptomatic paroxysmal atrial fibrillation (PAF). This system offers a new level of speed, control, and predictability for physicians, which makes it an ideal tool for AFib ablation. Thus, owing to the technological advancements and the focus on improving the healthcare system, it is expected that more companies will enter the market that may further drive the market growth in the future.
- In March 2021, Tempus announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids clinicians in identifying patients at increased risk of developing atrial fibrillation (AFib) or atrial flutter.
- In February 2021, Medtronic received approval from Food and Drug Administration (FDA) for DiamondTemp Ablation (DTA) system which treats patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is a temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Obesity and Heart Diseases
4.2.2 Rising Number of Programs to Enhance Public Awareness
4.3 Market Restraints
4.3.1 High Cost of Procedure
4.3.2 Regulatory Issues Associated with the Devices
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product
5.1.1 Catheter Ablation
5.1.2 Surgical Ablation
5.2 By End-User
5.2.2 Ambulatory Surgical Centers
5.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East and Africa
5.3.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Boston Scientific Corporation
6.1.2 Medtronic Plc
6.1.3 Biotronik SE & Co. KG
6.1.4 AtriCure, Inc.
6.1.5 Cardiofocus, Inc.
6.1.6 Abbott Laboratories
6.1.7 Advansta, Inc.
6.1.8 Johnson & Johnson
6.1.9 MicroPort Scientific Corporation
6.1.10 Koninklijke Philips N.V
6.1.11 Siemens AG
6.1.12 Osypka AG
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Atrial Fibrillation Surgery Market market is studied from 2018 - 2026.
What is the growth rate of Global Atrial Fibrillation Surgery Market?
The Global Atrial Fibrillation Surgery Market is growing at a CAGR of 12.2% over the next 5 years.
Which region has highest growth rate in Global Atrial Fibrillation Surgery Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Atrial Fibrillation Surgery Market?
North America holds highest share in 2020.
Who are the key players in Global Atrial Fibrillation Surgery Market?
- Boston Scientific Corporation
- Medtronic Plc
- AtriCure, Inc.
- Cardiofocus, Inc.
Are the major companies operating in Global Atrial Fibrillation Surgery Market.